Accepted Manuscript

The effect of flunixin meglumine, firocoxib and meloxicam on the uterine mobility of equine embryos

C.T.C. Okada, V.P. Andrade, C.P.F. Dell'Aqua, M. Nichi, C.B. Fernandes, F.O. Papa, M.A. Alvarenga

PII:	S0093-691X(18)30850-1
DOI:	10.1016/j.theriogenology.2018.09.026
Reference:	THE 14711
To appear in:	Theriogenology
Received Date:	01 April 2018
Accepted Date:	24 September 2018

Please cite this article as: C.T.C. Okada, V.P. Andrade, C.P.F. Dell'Aqua, M. Nichi, C.B. Fernandes, F.O. Papa, M.A. Alvarenga, The effect of flunixin meglumine, firocoxib and meloxicam on the uterine mobility of equine embryos, *Theriogenology* (2018), doi: 10.1016/j.theriogenology. 2018.09.026

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1The effect of flunixin meglumine, firocoxib and meloxicam on the2uterine mobility of equine embryos

3 C.T.C. Okada^a, V.P. Andrade^a, C.P.F. Dell'Aqua^a, M. Nichi^b, C.B. Fernandes^b, F.O. Papa^a, M.A.

Alvarenga^a

a. São Paulo State University - UNESP, Botucatu - SP – Brazil
b. University of São Paulo – USP, São Paulo – SP – Brazil

8 ABSTRACT

4

5

6

7

Embryo mobility occurs as a result of prostaglandin production by the embryo and 9 endometrium, promoting uterine smooth muscle contractions, which propels the 10 embryonic vesicle through the lumen. Non-steroidal anti-inflammatory drugs 11 (NSAIDs), as flunixin meglumine, are routinely used in equine medicine and can alter 12 the conceptus mobility if applied in early pregnancy, which may impair maternal 13 14 recognition of pregnancy. The objective of this study was to evaluate and compare the 15 effect of flunixin meglumine (FM; 1.1mg/kg IV), firocoxib (FIRO; 0.2mg/kg PO), and meloxicam (ML; 0.6mg/kg, IV), on the embryo mobility. Thirty mares were divided 16 into three groups (n=10 per treatment). After the pregnancy diagnosis on day 12 after 17 ovulation, the embryo mobility was evaluated by transrectal ultrasonography every five 18 minutes for one hour in order to visualize the location of the embryo. In all mares, three 19 evaluations were performed: immediately before treatment (pre-treatment), after 20 NSAID administration and 24 hours after treatment. In group FM, embryo mobility 21 decreased, from 5.8 ± 0.3 movements/hour (m/h) to 2.3 ± 0.5 m/h (p<0.05) and, after 24 22 hours the values were similar to the pre-treatment evaluation $(5.9 \pm 0.2 \text{ m/h})$. Likewise, 23 ML treatment caused a decrease of embryo movements, from 5.9 ± 0.3 to 1.9 ± 0.3 m/h 24 (p<0.05), 24 hours after treatment values were 5.7 ± 0.4 m/h. Treatment with FIRO did 25 not interfere with embryo mobility $(5.7 \pm 0.4; 5.8 \pm 0.3 \text{ and } 5.6 \pm 0.3 \text{ embryo}$ 26 movements in the first, second and third evaluation, respectively). In conclusion, FIRO 27 was the only NSAID that did not alter the embryo mobility and may be the safest 28 29 NSAID for use in early pregnant mares.

Keywords: embryo mobility, maternal recognition of pregnancy, nonsteroidal anti-inflammatory, prostaglandin.

Download English Version:

https://daneshyari.com/en/article/11025958

Download Persian Version:

https://daneshyari.com/article/11025958

Daneshyari.com